2019年-2025年全国医药制造业出口货值统计图 数据来源：国家统计局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 上市公司：国药现代（600420），昆药集团（600422），片仔癀（600436），千金药业（600479），津 药药业（600488），国药股份（600511），联环药业（600513），合富中国（603122），康惠制药 （603139），莎普爱思（603168），奥翔药业（603229），大参林（603233） 相关报告：智研咨询发布的《2026-2032年中国医药制造外包（CMO/CDMO）行业市场发展态势及未来 趋势研判报告》 根据国家统计局数据可知：2025年12月全国医药制造业出口货值为225.6亿元，同比下降3.5%；2025年 全国医药制造业累计出口货值为2367.2亿元，累计同比增长9.9%。 ...

Group 1 - The core viewpoint of the article highlights the growth and current state of the pharmaceutical manufacturing industry in China, particularly focusing on the increase in the number of enterprises in this sector [1] - As of January-November 2025, the number of pharmaceutical manufacturing enterprises reached 9,875, marking an increase of 82 enterprises compared to the same period last year, which represents a year-on-year growth of 0.84% [1] - The pharmaceutical manufacturing sector accounts for 1.88% of the total industrial enterprises in China, indicating its significance within the broader industrial landscape [1] Group 2 - The article references a report by Zhiyan Consulting that discusses the market development trends and future outlook for the Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) sectors in China from 2026 to 2032 [1] - The report emphasizes the importance of in-depth industry research and tailored consulting services provided by Zhiyan Consulting, which has been active in the industry research field for over a decade [1]

Core Viewpoint - The report highlights the growth and trends in China's pharmaceutical manufacturing outsourcing (CMO/CDMO) industry, indicating a positive trajectory in export values and market development from 2026 to 2032 [1] Industry Summary - In November 2025, the total export value of China's pharmaceutical manufacturing industry reached 18.97 billion, marking a year-on-year increase of 1.6% [1] - From January to November 2025, the cumulative export value of the pharmaceutical manufacturing industry was 214.06 billion, with a year-on-year growth of 11.7% [1] - The report includes a statistical chart of the export value of the pharmaceutical manufacturing industry from 2019 to November 2025, showcasing the growth trend over the years [1] Company Summary - Listed companies mentioned include: Guoyao Modern (600420), Kunming Pharmaceutical Group (600422), Pian Zai Huang (600436), Qianjin Pharmaceutical (600479), Tianyao Pharmaceutical (600488), Guoyao Shares (600511), Lianhuan Pharmaceutical (600513), Hefei China (603122), Kanghui Pharmaceutical (603139), Shapuaisi (603168), Aoxiang Pharmaceutical (603229), and Daclin (603233) [1] - The report is published by Zhiyan Consulting, a leading industry consulting firm in China, specializing in in-depth industry research and providing comprehensive solutions for investment decisions [1]